A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant.

A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant.

<h4>Background</h4>Allogeneic hematopoietic stem cell transplantation (HCT) is an often curative intent treatment, however it is associated with significant gastrointestinal (GI) toxicity and treatment related mortality. Graft-versus-host disease is a significant contributor to transplan...

Full description

Bibliographic Details
Main Authors: Sendhilnathan Ramalingam, Sharareh Siamakpour-Reihani, Lauren Bohannan, Yi Ren, Alexander Sibley, Jeff Sheng, Li Ma, Andrew B Nixon, Jing Lyu, Daniel C Parker, James Bain, Michael Muehlbauer, Olga Ilkayeva, Virginia Byers Kraus, Janet L Huebner, Thomas Spitzer, Jami Brown, Jonathan U Peled, Marcel van den Brink, Antonio Gomes, Taewoong Choi, Cristina Gasparetto, Mitchell Horwitz, Gwynn Long, Richard Lopez, David Rizzieri, Stefanie Sarantopoulos, Nelson Chao, Anthony D Sung
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0252995

Internet

https://doi.org/10.1371/journal.pone.0252995

Similar Items